Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014075 | 0.92 | ALDH1A1 (0.73) | ALDH1A1KMT2ATHRBHSD17B10ATM | |
| SCHEMBL321816 | 0.83 | TSHR (0.59) | ALDH1A1KMT2ATSHRLMNAMAPT | |
| SCHEMBL21963567 | 0.82 | KMT2A (0.78) | ALDH1A1KMT2ATHRBATMCYP1A2 | |
| SCHEMBL21963581 | 0.82 | KMT2A (0.72) | ALDH1A1KMT2ATHRBHSD17B10ATM | |
| Methyl Nicotinate SCHEMBL28918156 | 0.81 | ALDH1A1 (0.93) | ALDH1A1KMT2AHSD17B10ATMTSHR | |
| Methyl Nicotinate SCHEMBL24566 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AHSD17B10ATMTSHR | |
| Methyl Nicotinate SCHEMBL820747 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AHSD17B10ATMTSHR | |
| Methyl Nicotinate SCHEMBL29386553 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KMT2AHSD17B10ATMTSHR | |
| Methyl Nicotinate SCHEMBL11491005 | 0.80 | ALDH1A1 (0.96) | ALDH1A1KMT2AHSD17B10ATMTSHR | |
| Methyl Nicotinate SCHEMBL30541951 | 0.80 | ALDH1A1 (0.96) | ALDH1A1KMT2AHSD17B10ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2022-01-13 | — | — | US | disclosed |
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2022-01-13 | — | — | US | disclosed |
| WO-2020100169-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020100169-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | INCILIA THERAPEUTICS PRIVATE LIMITED (IN) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009892-A1 | SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF | PC, PCCA, GLS2 | ALDH1A1 255/4885KMT2A 2224/4885THRB 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.